Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4dbeab7c420445e258c1383878607491 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
filingDate |
2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deaef2e4a0bd206315d38c5761a26513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7fad7030e11bdfaa02704c4d4a52f0f |
publicationDate |
2021-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CZ-2020437-A3 |
titleOfInvention |
Use of heme arginate for the manufacture of a medicament for the treatment of beta coronavirus infection |
abstract |
The solution is to use heme arginate for the manufacture of a medicament for the treatment of beta coronavirus infection, as heme arginate has been found to inhibit the replication of beta coronaviruses, especially SARS-CoV-2 and related beta coronaviruses SARS or MERS, while protecting infected cells from damage. |
priorityDate |
2020-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |